공시 • 21h
Talon Resources plc Announces Board Changes Talon Resources PLC announced that, at the General Meeting held on June 22, 2026, all resolutions were duly passed. On Admission, Alex King, Ben Hodges, Kiran Morzaria and Bert Monro will join the Board and Charlie Wood and Sarah Cope will step down from their positions as directors. 공시 • May 27
Talon Resources plc has filed a Follow-on Equity Offering in the amount of £2 million. Talon Resources plc has filed a Follow-on Equity Offering in the amount of £2 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 160,000,000
Price\Range: £0.0125 공시 • May 18
Talon Resources plc Requests Cancellation of Listing of Ordinary Shares from London Stock Exchange Talon Resources plc ("Talon" or the "Company") announced that it has requested the Financial Conduct Authority (FCA) to cancel the listing of its ordinary shares of £0.01 each (the "Shares") from the Equity Shares (Shell Companies) category of the Official List and to request the London Stock Exchange to cancel the admission to trading of the Shares on its Main Market for listed securities (together, the "Cancellation"). The Company further announces that it intends to apply for the admission of the Shares to trading on AIM ("Admission"). It is expected that Cancellation and Admission will occur simultaneously. In accordance with Listing Rule 5.2.8, the Company is required to give at least 20 business days' notice of the intended Cancellation. Accordingly, it is expected that the Cancellation will become effective from 8.00 a.m. on June 16, 2026, with the last day of trading of the Shares on the Main Market being June 15, 2026. The Directors believe that AIM represents a more appropriate market for the Company given the size and stage of development, offering a more flexible regulatory environment, particularly in relation to corporate transactions, and access to a broader pool of institutional and other investors. Admission is expected to become effective, and dealings in the Shares are expected to commence on AIM, at 8.00 a.m. on June 16, 2026. 공시 • Mar 25
Medcaw Investments Plc announced that it has received £0.024 million in funding Medcaw Investments Plc announced a private placement to issue unsecured Convertible Loan Notes for the proceeds of £24,000 on March 25, 2026. The conversion price is £0.01. In addition, the CLN holder will, upon conversion, be granted warrants to subscribe for one new ordinary share for every two shares received on conversion. The warrants will carry an exercise price of £0.03 per share and will be exercisable for a period of 12 months from the date of grant. Board Change • Nov 11
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Chairman Marcus Yeoman was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. 공시 • Sep 24
Medcaw Investments Plc announced that it has received £0.425 million in funding Medcaw Investments Plc announced private placement of unsecured convertible loan notes for gross proceeds of GBP 425000 on September 24, 2025.The Notes carry an annual coupon of 6%, which is payable on redemption. In the event of non-payment on redemption, default interest will accrue at a rate of 12% per annum. The Notes are redeemable at par on the first anniversary of issue, or earlier in the event of a material breach, insolvency or other event of default. In addition, Noteholders will, upon conversion, be granted warrants to subscribe for one new ordinary share for every two shares received on conversion. The warrants will carry an exercise price of GBP 0.03 per share and will be exercisable for a period of 12 months from the date of grant. No application has been, or will be, made for the Notes to be admitted to trading on any market. Board Change • Sep 15
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Chairman Marcus Yeoman was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Jul 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Chairman Marcus Yeoman was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. 공시 • Jun 04
Medcaw Investments Plc, Annual General Meeting, Jun 26, 2025 Medcaw Investments Plc, Annual General Meeting, Jun 26, 2025. Location: the offices of investec bank plc, eccleston yards, 25 eccleston place, sw1w 9nf, london United Kingdom Board Change • May 20
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Chairman Marcus Yeoman was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. New Risk • Apr 16
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-UK£54k). Revenue is less than US$1m. Market cap is less than US$10m (UK£885.3k market cap, or US$1.17m). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Board Change • Apr 14
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Chairman Marcus Yeoman was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. 공시 • Oct 05
Medcaw Investments Plc, Annual General Meeting, Oct 29, 2024 Medcaw Investments Plc, Annual General Meeting, Oct 29, 2024. Location: eccleston yards, 25 eccleston place, sw1w 9nf, london United Kingdom 공시 • Sep 28
Medcaw Investments Plc (LSE:MCI) has entered into a conditional implementation agreement to acquire Abyssinian Metals Limited. Medcaw Investments Plc (LSE:MCI) has entered into a conditional implementation agreement to acquire Abyssinian Metals Limited on July 7, 2024. The consideration consists of common equity of Medcaw Investments Plc to be issued for common equity of Abyssinian Metals Limited. As part of consideration, an undisclosed value is paid towards common equity of Abyssinian Metals Limited. Subject to the Company being satisfied with technical, legal, accounting, tax, financial, commercial and environmental due diligence on AML the Company will consider making an offer to acquire up to 100% of the entire issued share capital of AML ("AML Shares") in consideration for the issue and allotment of new ordinary shares ("Ordinary Shares") in the Company to the shareholders of AML ("Proposed Transaction”). As at the date of this announcement no decision has made by the Company whether to proceed with an offer for the AML Shares or otherwise and there is no offer that is capable of being accepted by the shareholders of AML.
If completed, the Proposed Transaction will constitute a reverse takeover under the Listing Rules. The Company is currently unable to provide full disclosure under Listing Rule 5.6.15 in relation to AML and it has requested a suspension of trading in its shares with immediate effect. The trading of the Company’s shares will remain suspended until such time as a prospectus is published in relation to the Proposed Transaction or the Company announces that the discussions have been terminated.
Subject to satisfactory due diligence any formal offer by the Company for the shares in AML is expected to be conditional on: receiving acceptances under the Offer from shareholders of AML holding at least 51% of the voting rights of AML; if required, a waiver by the UK Takeover Panel (the “Panel”) in respect of the obligations under Rule 9 of the Takeover Code on the shareholders of AML to make a mandatory offer for the shares in the Company having been granted; if required, approval by shareholders of Medcaw Investments of the waiver granted by the Takeover Panel and as required any other approvals of the shareholders of the Company having been granted; there having been no material adverse change in the business, results of operations, condition (financial or otherwise) or prospects of AML or any of its subsidiaries from the date prior to completion of the Proposed Transaction and various board and shareholder approvals. 공시 • Jun 16
Medcaw Investments Plc, Annual General Meeting, Jun 28, 2023 Medcaw Investments Plc, Annual General Meeting, Jun 28, 2023, at 10:00 Coordinated Universal Time. Location: offices of Orana Corporate LLP, Eccleston Yards, 25 Eccleston Place London United Kingdom 공시 • Dec 22
Medcaw Investments Plc has completed an IPO in the amount of £0.637082 million. Medcaw Investments Plc has completed an IPO in the amount of £0.637082 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 6,370,820
Price\Range: £0.1